APLS - CIK 0001492422
Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $1.00B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $1.00B | +28.5% |
| FY 2024 | $781.37M | +97.0% |
| FY 2023 | $396.59M | +425.8% |
| FY 2022 | $75.42M | +13.3% |
| FY 2021 | $66.56M | -73.4% |
| FY 2020 | $250.65M | - |
Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $1.00B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Apellis Pharmaceuticals, Inc.'s revenue grew from $250.65M to $1.00B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.